Dapsone agranulocytosis in a leprosy patient.
Dapsone-induced agranulocytosis is a rare adverse effect. There are various reports of agranulocytosis in patients treated with dapsone for malaria prophylaxis and other dermatological diseases. However, this adverse reaction in leprosy is not often encountered. We describe agranulocytosis in a young patient who was taking dapsone (100 mg) for borderline-tuberculoid leprosy in a rural environment.
Hiran
S
S
Department of Internal Medicine, J L N Hospital & Research Centre, (MP), India.
Pande
T K
TK
Pani
S
S
Vishwanathan
K A
KA
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000503:physiopathology; D003622:Dapsone / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007918:Leprosy / Q000175:diagnosis / Q000188:drug therapy*
D007917:Leprostatic Agents; D003622:Dapsone